The GPRC5D-directed Therapies Market is emerging as one of the most promising areas in oncology, offering new hope for patients with relapsed or refractory multiple myeloma. GPRC5D (G protein-coupled receptor class C group 5 member D) has garnered attention for its selective expression on malignant plasma cells and limited presence in normal tissues, making it an ideal target for...